AMG 355 / Amgen - LARVOL DELTA

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting | N=535 ➔ 77

Enrollment change • Enrollment closed • First-in-human • Monotherapy • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=535 | Recruiting | Sponsor: Amgen | Trial completion date: Dec 2028 ➔ Mar 2028 | Trial primary completion date: Mar 2028 ➔ Mar 2027

First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=535 | Recruiting | Sponsor: Amgen | Trial completion date: Feb 2028 ➔ Jan 2029 | Trial primary completion date: Feb 2027 ➔ Mar 2028

Monotherapy • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Solid Tumor

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=515 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Monotherapy • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor